The global burden of bovine tuberculosis (bTB) remains poorly characterized, with spill-over impacts on multiple species. The "One Health" concept is especially relevant given the bidirectional risk of cattle infecting humans with Mycobacterium bovis and humans infecting cattle with Mycobacterium tuberculosis. "Test and cull" is the tradi- an understanding of the induction of mucosal immunity against bTB. We summarize discussions on the use of BCG vaccination in domestic animals and wildlife and list potential projects to address the knowledge gaps identified.
| INTRODUCTION
The German pathologist Rudolph Virchow coined the term "zoonosis" to describe diseases common to humans and animals (Thirunavukkarasu, Plain, de Silva, Marais, & Whittington, 2017) ; preceding our appreciation that the majority of infectious diseases affecting humans today have an animal origin (Wolfe, Dunavan, & Diamond, 2007) . In recent times growing international trade and travel, as well as increased ecosystem fragmentation and human-animal contact, have facilitated the emergence and spread of pathogenic organisms (Hill-Cawthorne, Capon, Sorrell, & Marais, 2017; Rabinowitz, Scotch, & Conti, 2009) . The "One Health" concept acknowledges that the health of humans and animals is closely interlinked and emphasizes the fact that all animals (including humans) provide a potential reservoir for pathogenic species (Thirunavukkarasu et al., 2017) . Bovine tuberculosis presents a classic One Health challenge, since disease reduction in cattle will improve bovine health, and at the same time will reduce health risks to humans and wildlife.
Bovine tuberculosis (bTB) has proved to be an intractable problem in many countries, particularly in settings where "test and cull" policies are not affordable or socially acceptable, or in areas where Mycobacterium bovis infection is sustained by wildlife reservoirs. Indications are that bTB causes a substantial global disease burden (WHO, 2018) , but in the absence of reliable surveillance data it is impossible to assess the true incidence of M. bovis infection in humans, domestic cattle and camelids and various wildlife species.
Although humans mostly acquire M. bovis infection from cattle (Amato et al., 2018; Sandoval-Azuara et al., 2017) , indications are that in some parts of the world cattle with presumed bTB may in fact be infected with Mycobacterium tuberculosis and not M. bovis (Hlokwe, Said, & Gcebe, 2017; Mittal et al., 2014; Sweetline, Ronald, Kumar, Kannan, & Thangavelu, 2017) ; reflecting likely human to cattle transmission of tuberculosis (TB). These examples of "reverse zoonosis" provide a powerful reminder that pathogen transmission between animals and humans is bidirectional. Genomic evidence indicates that human TB caused by M. tuberculosis did not evolve from M. bovis as previously thought; in fact, animal strains included in the M. tuberculosis complex likely evolved from ancestral human strains, although further elucidation is required (Smith, Hewinson, Kremer, Brosch, & Gordon, 2009 ).
Globally, the annual costs to deal with bTB have been estimated to be US$3 billion (WHO, 2018) . India has the largest population of cattle in the world -around 300 million -of which an estimated 22 million are infected with M. bovis (Srinivasan et al., 2018) , but bTB control efforts are compromised by inadequate disease surveillance and religious objections to the slaughter of infected animals.
As in other parts of the developing world, cattle are mainly kept in small holdings and represent a major source of livelihood, nutrition and cultural wealth. Given the limited efficacy of traditional bTB containment methods in large parts of the world, it seems important to reassess the value of alternative approaches, especially the potential benefits of bacille Calmette-Guerin (BCG) vaccination. BCG vaccination has been used in humans for nearly 100 years, but its use in animals remains limited, despite the fact that Calmette and Guerin tested BCG in cattle in 1911; 10 years before its use in humans (Waters, Palmer, Buddle, & Vordermeier, 2012) . With the exception of Great Britain where BCG vaccine has been licensed for the use in badgers (made possible by the licensing in 2010 of BCG for intramuscular administration to badgers -BadgerBCG ® ) (Perrett et al., 2018) , widespread use of BCG in animals has not been implemented. The group identified key knowledge gaps and research needs in bTB control, and articulated the rationale for specific studies to address these research needs (Table 1) 
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| EFFICACY OF ORAL BCG
Although human BCG today is primarily administered through the intradermal route, oral BCG administration has a long history and was used in multiple controlled studies performed in the 1920s and 1930s; demonstrating significant protection against TB (Aronson & Dannenberg, 1935; Kerszturi, 1929) . More recent studies showed that oral BCG administration induces mucosal immunity, with enhanced TB-specific secretory IgA, T-cell homing to restricted lung mucosal compartments and bronchoalveolar lavage recovery of these T-cells, compared to intradermal vaccination (Hoft et al., 2018; Lai, Afkhami, Haddadi, Jeyanathan, & Xing, 2015) . In studies using rhesus macaques, pulmonary mucosal BCG vaccination conferred enhanced protection compared to standard intradermal BCG (Verreck et al., 2017) , and it seems preferable to match the route of vaccination and natural infection (Manjaly & McShane, 2015) . In cattle, the route of transmission is primarily by aerosol, although calves are commonly infected through ingestion of infected milk, while for wildlife, transmission can be via a variety of routes involving aerosol inhalation or oral ingestion.
Therefore, induction of mucosal immunity could be beneficial and oral vaccination with BCG might be advantageous. Preliminary research into the use of oral BCG to protect cattle against bTB has been encouraging, (Buddle, Vordermeier, Chambers, & de KlerkLorist, 2018; Nugent, Yockney, Whitford, Aldwell, & Buddle, 2017) as has been its application in wildlife reservoirs, such as possums in New Zealand (Tompkins et al., 2009 ) and badgers in Ireland (Gormley, Ní Bhuachalla, O'Keeffe, Murphy, & Aldwell, 2017) . This experience, as well as the effective administration of rabies vaccine using bait, suggests that oral administration of BCG vaccine might be the most cost-effective means of vaccinating wildlife (Pastoret & Brochier, 1996) .
| BCG VACCINATION OF CATTLE
Studies over the past two decades have demonstrated that BCG vaccination of cattle can be a valuable tool in bTB control, especially in settings where "test and cull" is not an option or persistent wildlife reservoirs are difficult to eradicate . Experimental challenge studies have identified many of the variables which influence BCG efficacy in cattle. Although BCG vaccination does not induce complete protection, no single vaccine has proven to be more efficacious than BCG to protect cattle against bTB. Recent studies have shown that similar levels of protection were induced when BCG was applied parenterally or orally, although higher doses were required for oral vaccination . The highest level of efficacy was achieved when calves were vaccinated at <1 month of age, followed by a revaccination boost at 12-24 months to prevent waning immunity (Parlane et al., 2014) . Although assessment of BCG as an effective bTB control strategy is challenging (Conlan, Vordermeier, de Jong, & Wood, 2018) is not complete and vaccination should be integrated with other control measures that are feasible in the study setting, such as T A B L E 1 Bovine TB knowledge gaps and research needs identified at the Jerusalem workshop
Knowledge gap Research need
Poorly quantified prevalence of Mycobacterium bovis infection and disease in humans, cattle, camelids, buffaloes and other relevant wildlife
• Existing bTB surveillance data provide local snapshots, but fail to provide a global overview of the situation • bTB and M. bovis infection surveillance systems (animals and humans) in the less developed parts of the world are poorly developed or dysfunctional • Poor communication between human and animal health branches of government limit the exchange of relevant surveillance data • African buffaloes and American bison are important bTB reservoirs; the contribution of water buffaloes in Asian settings is poorly documented • M. bovis infection is not restricted to bovines. It may be a significant problem in domestic camelids, but the prevalence is unknown • Good surveillance data are essential to prioritize intervention sites, especially if current BCG trials in cattle demonstrate success What to do when "test and cull" is not an option?
• "Test and cull" is unfeasible in settings where it is not economically viable, where cultural or religious objections exist, or where wild animal reservoirs exist in protected species • Settings where infected cows are long-lived pose the greatest risk, since they could spread infection for prolonged periods of time. More studies should track the natural history of disease and epidemic spread of bTB in settings where infected animals cannot be culled
Use of BCG to reduce bTB in domestic animals and wildlife
• Proof of principle studies demonstrated significant bTB protection in cattle and wildlife, such as possums in New Zealand and badgers in the Great Britain/Ireland • BCG has shown good protection against TB in humans and animals, but large-scale studies in animals are lacking and few studies have investigated the use of oral BCG in problematic wildlife reservoirs • Novel BCG formulations and pragmatic delivery methods require careful consideration in relevant animal species • Limited research has investigated how M. bovis infection spreads within local ecosystems and how this can be contained. The conservation value of BCG vaccination in iconic wildlife species such as the African buffalo, and spill-over carnivore species such a lions and African wild dogs has not been considered BCG: M. bovis bacille Calmette-Guerin; bTB: bovine tuberculosis, mostly caused by Mycobacterium bovis; TB: tuberculosis, mostly caused by M. tuberculosis.
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| 1039 segregating bTB infected cows and feeding young calves born to infected mothers with pasteurized milk or with milk from noninfected cows. In some settings, it will also be important to minimize contact between cattle and infected wildlife reservoirs. A recent report from the Great Britain recommended a thorough re-examination of different BCG vaccination models once DIVA tests have been refined and tested, with careful cost-benefit analysis that takes into account potential implications for the International and United Kingdom trade (Godfray, Donnelly, Hewinson, Winter, & Wood, 2018) .
| BCG VACCINATION OF OTHER DOMESTICATED SPECIES
The dromedary camel (Camelus dromedarius) is extremely important for the livelihood of pastoral communities in arid areas of the world, including North Africa and the Middle East providing transportation, milk and meat. Camel milk and cheese are traditionally consumed raw, which combined with close physical human-animal contact, creates a public health concern for TB transmission. Camel TB has been reported in Egypt (Elmossalami, Siam, & El Sergany, 1971) , the Uni- concern, Brucella prevalence and vaccination efficacy could be determined at the same time. These surveillance and intervention studies will also provide a platform to determine the burden of other diseases, such as parasitic infections, improving the health and wellbeing of highly prized and culturally significant camel herds.
| BCG VACCINATION OF WILD ANIMALS
The requirements for the vaccination of wildlife M. bovis reservoirs differ from those of domestic animals in that it would be preferable if wildlife could receive a single vaccination dose and, for practical purposes, if the vaccine could be self-administered via an oral bait.
Vaccination would mainly aim to decrease TB transmission among wildlife and spread to domestic animals. The use of bait BCG vaccines for possums in New Zealand and badgers in Ireland resulted in significant TB protection (Gormley et al., 2017; Tompkins et al., 2009 ). Oral BCG vaccination of wild boar and deer also induced protection against challenge with M. bovis (Gortázar et al., 2014; Nol et al., 2008) . To date, BCG vaccination has been shown to be safe in all animal species tested (Murphy, Corner, & Gormley, 2008; Perrett et al., 2018) . Oral vaccination of wildlife could be a useful tool for control of TB in wildlife; and studies are required to optimize the dose and bait formulations, and to develop delivery systems that prevent uptake by non-target species such as cattle, where BCG bait consumption could result in the animal subsequently testing positive using a traditional TST.
Within South Africa, M. bovis infection has been reported in wildlife populations for nearly a century (Jolles, Cooper, & Levin, 2005; Paine & Martinagliau, 1928) . It is currently endemic in the Greater Kruger National Park Complex and the Hluhluwe-iMfolozi Park (Hlokwe et al., 2011; Michel et al., 2009) , as well as several private farms and conservancies (Hlokwe, De Klerk-Lorist, & Michel, 2016 , South African Department of Agriculture, Forestry and Fisheries annual disease reports). African buffaloes are well-known maintenance hosts of TB (Michel & Bengis, 2012) and play an important role in TB spillover to other wildlife species (Michel et al., 2006) , as well as "spill-back" to domestic cattle (Musoke, Hlokwe, Marcotty, du Plessis, & Michel, 2015) . Some rare and endangered species have Since neither "test and cull" nor treatment is a viable option in the majority of wildlife species, the only realistic alternative is vaccination. Studies in the African buffalo (Syncerus caffer) would be important to determine whether BCG vaccination offers herd-level protection against bTB in free ranging African buffalo populations.
Preliminary studies in semi-free-ranging buffalo have been disappointing, but various factors such as the age of the animals, the vaccination route, the challenge dose and grazing limitations could have contributed to the negative outcome (de Klerk, Michel, Bengis, Kriek, & Godfroid, 2010) . More buffalo studies are important since they represent an important wildlife TB reservoir, with spillover to other key species. Their limited dispersion should also facilitate vaccine delivery and monitoring of herd-level impacts.
| CONCLUSION
Considering the human disease burden, the economic cost of livestock disease and the negative conservation impact resulting from bTB, judicious use of BCG vaccination in settings where "test and cull" is not an option requires urgent consideration. Collecting accurate surveillance data is important to help prepare field sites for future intervention trials. Research on optimal BCG formulations and delivery methods should be advanced by addressing strain composition, dosage and administration method, as well as vaccine supply.
We are endeavouring to develop two animal BCG research programs; one focused on zoonotic disease risk in domestic camelids, and the second on the conservation of iconic African wildlife, focusing on the African buffalo and relevant "spill-over" species.
